^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Ovarian Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

    Excerpt:
    Women with platinum-resistant, histologically confirmed epithelial ovarian, fallopian tube or peritoneal cancer...EGF-R expression must be positive (e.g., 1+ or greater)...
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.

    Published date:
    05/13/2020
    Excerpt:
    Of the 16 patients, 81% patients (n = 13) had progressive disease, 12.5% stable disease (n = 2), and 6% partial response....This prospective phase I/II clinical trial failed to show sufficient clinical activity of topotecan in combination with gefitinib in patients with EGFR-positive recurrent ovarian...
    Secondary therapy:
    topotecan
    DOI:
    10.1200/JCO.2020.38.15_suppl.6059